Patents by Inventor Robert Balint

Robert Balint has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Proteins and methods useful for assessing risk of cardiovascular disease
    Publication number: 20060034819
    Abstract: The invention relates to a mutant protein comprising at least a fragment of a mutant dimethylarginine dimethylaminohydrolase (DDAH) enzyme, wherein the fragment possesses an affinity for asymmetric N,N-dimethyl arginine (ADMA) and/or L,N-monomethylarginine (LNMMA), which exists at lower plasma levels than ADMA, and is deficient in hydrolyzing ADMA or LNMMA to citrulline, releasing citrulline, or both.
    Type: Application
    Filed: October 7, 2005
    Publication date: February 16, 2006
    Inventors: Robert Balint, John Cooke
  • Antibody specificity transfer using minimal essential binding determinants
    Publication number: 20050255552
    Abstract: The present invention provides methods of making antibodies having the binding specificity of a reference antibody. Antibodies generated by the methods of the inventions have at least one minimal essential binding specificity determinant from a heavy chain or light chain CDR3 from the reference antibody. The method can be used, e.g., in humanization procedures. The invention also provides libraries and antibodies made in accordance with the methods.
    Type: Application
    Filed: January 20, 2005
    Publication date: November 17, 2005
    Applicant: KaloBios, Inc.
    Inventors: Peter Flynn, Kenneth Luehrsen, Robert Balint, Jeng-Horng Her, Christopher Bebbington, Geoffrey Yarranton
  • Antibody affinity engineering by serial epitope-guided complementarity replacement
    Publication number: 20050008625
    Abstract: This invention provides for a novel means for obtaining human idiologs for any non-human antibody to any target by epitope guided replacement of variable regions using competitive cell-based methods in which the competitor can be either the reference antibody or a ligand that binds to the same epitope on the target as the reference antibody.
    Type: Application
    Filed: February 13, 2004
    Publication date: January 13, 2005
    Applicant: KaloBios, Inc.
    Inventors: Robert Balint, Jeng-Horng Her